We are still falling into the same trap: every histology (breast, prostate, lung, etc.) is being forced to prove the OMD hypothesis independently in its own RCT. It’s not that histology doesn’t matter, but it might be a distraction in the OMD local control setting. 2/n
New @Nature study: >50% of lung cancer metastases are seeded by other metastases, not the primary tumor. This "seeding from seeding" reveals a complex evolutionary cascade that allows cancer to colonize the body.
https://t.co/lYUyfRYOcP
God’s heart is torn apart by wars, violence, injustice and lies. But our Father’s heart is not with the wicked, the arrogant, or the proud. God’s heart is with the little ones and the humble, and with them He builds up His Kingdom of love and peace day by day. Wherever there is love and service, God is there. #ApostolicJourney #Algeria
In his strongest condemnation yet of the Trump-Vance war against Iran, Pope Leo XIV said today:
“We are surrounded by a delusion of omnipotence that’s becoming increasingly unpredictable and aggressive.”
“We are met by threats instead of invitations to come together.
“Those who pray don’t threaten death. Death enslaves those who have turned their backs on God and turned themselves and their own power into a mute, blind, and deaf idol.
“They demand the whole world bends their knee. Enough of the idolatry of self and money! Enough of the display of power! Enough of war!
“True strength is shown in serving life!”
📌 Top 10 Tips for Stereotactic Body Radiation Therapy Contouring and Planning in Oligometastatic Disease: Lessons Learned From the UK SBRT QA Program ☢️
🔗 https://t.co/WkZDZSoA4I @OncoAlert#OncoAlertAF@IJROBP@fifimcdrmh@royalmarsdenNHS 🔹Standardize definitions. 🔸 Optimize use of supporting imaging.
🔹 Motion management.
🔸 Optimize patient preparation.
🔹 Use all available TPS tools to optimize contouring.
🔸 Check auto-contouring output.
🔹 Appropriate use of OAR dose-volume constraints.
🔸 Maximize PTV coverage.
🔹 Conform tightly to the PTV.
🔸 Managing multiple lesions.
Imagine 4 new anticancer drugs Pallituzumab, Geriatriximab, Symptomab, & Exercizumab hit the market. They should dominate the plenary sessions at ASCO & command billion-dollar revenue. But they don't because they're nonpharmacologic & shame on us.
Read our opinion piece in @JCO_ASCO
https://t.co/UFuxuDI3sn
Well….come and listen to the Lungtech talk tomorrow at 3.45 ▶️ risk of severe late toxicity was clinically significant with 60/8 in central tumours ▶️importance of multi- centre prospective trials @EORTC#ESTRO23
@nickva1 presenting the outcomes so far from the PACE trials. Radiotherapy now very well tolerated for vast majority of men, due to ongoing innovation radiotherapy. Much more to come yet! @royalmarsdenNHS@ICR_CTSU@EmmaHall71@Accuray
LO Pritam Singh:
Mr Speaker, please allow me to list just a few of our policy proposals to demolish this idea that the Workers’ Party has not put forward serious alternatives.
“The combination of metastasis-directed radiation and intermittent hormone therapy significantly improved progression free-survival for patients with oligometastatic disease,” says Dr. Chad Tang. Read the research: https://t.co/1G2dSeuHaU @ChadTangMD#ProstateCancer#EndCancer
(7/11)☢️✅Radiotherapy with standard hormone therapy also improved survival for men with a low metastatic burden (the cancer had not spread far).
☢️❎But for those with a high metastatic burden, radiotherapy did not help patients live longer.
Results👇
https://t.co/uuDVKeRGu7
R&O: "Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer – Results of a large multicenter analysis" https://t.co/3ZFrRj6Dii